Health Trials

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis

ConditionPsoriasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut Pasteur

About this trial

This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).

Eligibility criteria

Qualifiers

Adults (>18 years)

Presenting with cutaneous psoriasis

Patients have signed an informed consent

Beneficiary of the health insurance, except for the AME Only for patients of Group 1

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Blood sample
  • Data collection
  • skin biopsies

Treatment groups

90 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Institut Pasteur

Lead sponsor

Janssen Biotech, Inc.

Collaborator

Source ClinicalTrials.gov